Pharma Mar SA (PHM) Price & Analysis

Compare

12 Followers

PHM Stock Chart & Stats

Day’s Range― - ―

52-Week Range€27.98 - €105.80

Previous CloseN/A

Volume4.24K

Average Volume (3M)52.16K

Market Cap

$1.37B

Enterprise Value€1.30B

Total Cash (Recent Filing)€149.81M

Total Debt (Recent Filing)€42.63M

Price to Earnings (P/E)51.2

Beta1.19

Next Earnings

Jul 24, 2025

EPS Estimate

0.32

Last Dividend Ex-Date

Jun 12, 2024

Dividend Yield0.76%

Share Statistics

EPS (TTM)1.48

Shares Outstanding18,222,227

10 Day Avg. Volume36,777

30 Day Avg. Volume52,160

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)N/A

Price to Sales (P/S)3.67

Price to Cash Flow (P/CF)18.80

P/FCF Ratio-41.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$108.00

Price Target Upside33.17% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

---

Pharma Mar SA News

PremiumCompany Announcements

PharmaMar Reports Strong Q1 2025 Financial Growth

1d ago

PremiumCompany Announcements

Pharma Mar Announces 2025 Shareholders Meeting with Key Governance Proposals

1d ago

PremiumPre-Earnings

Is PHMMF a Buy, Before Earnings?

4d ago

PremiumCompany Announcements

Pharma Mar SA Reports on Recent Share Buy-Back Activities

4d ago

PremiumCompany Announcements

Pharma Mar Adjusts Financial Strategy with New Share Buyback Program

22d ago

PremiumCompany Announcements

Pharma Mar’s Credit Rating Maintained at ‘BB+’

22d ago

PremiumCompany Announcements

Pharma Mar Partners with Merck for Japanese Launch of Cancer Drug

23d ago

PremiumCompany Announcements

Pharma Mar Implements Share Delivery Plan to Boost Employee Engagement

23d ago

See All ES:PHM News

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

― Insiders

2.34%

Mutual Funds

― Other Institutional Investors

93.78% Public Companies and

Individual Investors

Detailed Ownership Overview >

PHM FAQ

What was Pharma Mar SA’s price range in the past 12 months?

Pharma Mar SA lowest stock price was €27.98 and its highest was €105.80 in the past 12 months.

What is Pharma Mar SA’s market cap?

Pharma Mar SA’s market cap is $1.37B.

When is Pharma Mar SA’s upcoming earnings report date?

Pharma Mar SA’s upcoming earnings report date is Jul 24, 2025 which is in 90 days.

How were Pharma Mar SA’s earnings last quarter?

Currently, no data Available

Is Pharma Mar SA overvalued?

According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharma Mar SA pay dividends?

Pharma Mar SA pays a Annually dividend of €0.526 which represents an annual dividend yield of 0.76%. See more information on Pharma Mar SA dividends here

What is Pharma Mar SA’s EPS estimate?

Pharma Mar SA’s EPS estimate is 0.32.

How many shares outstanding does Pharma Mar SA have?

Pharma Mar SA has 18,222,227 shares outstanding.

What happened to Pharma Mar SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pharma Mar SA?

Currently, no hedge funds are holding shares in ES:PHM

---

Pharma Mar SA Stock Smart Score

Outperform

Fundamentals

Return on Equity

13.06%

Trailing 12-Months

Asset Growth

-3.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

---

PHM Earnings Call

Q4 2025

0:00 / 0:00

---

PHM Stock 12 Month Forecast

Average Price Target

€108.00

▲(33.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"€26","109":"€109","46.75":"€46.8","67.5":"€67.5","88.25":"€88.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108.00000031941649,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€108.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.0012024872,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€108.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.00000031941649,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€108.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,46.75,67.5,88.25,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2020","6":"Oct<br/>2022","9":"Apr<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.8,96.73846156303203,97.67692312606407,98.6153846890961,99.55384625212815,100.49230781516019,101.43076937819222,102.36923094122426,103.3076925042563,104.24615406728833,105.18461563032037,106.12307719335242,107.06153875638445,{"y":108.00000031941649,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.8,96.73855403747692,97.67710807495385,98.61566211243077,99.55421614990769,100.49277018738462,101.43132422486154,102.36987826233846,103.30843229981538,104.24698633729231,105.18554037476923,106.12409441224615,107.06264844972308,{"y":108.0012024872,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.8,96.73846156303203,97.67692312606407,98.6153846890961,99.55384625212815,100.49230781516019,101.43076937819222,102.36923094122426,103.3076925042563,104.24615406728833,105.18461563032037,106.12307719335242,107.06153875638445,{"y":108.00000031941649,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.739,"date":1596240000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":84.739,"date":1598918400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":84.739,"date":1601510400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":84.739,"date":1604188800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":84.739,"date":1604188800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":55.111,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.669,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.986,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.845,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.381,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Almirall

―

0K9H

Faes Farma

―

0RDU

Grifols

―

0ILL

Laboratorios Farmaceuticos Rovi

―

NXT

Nueva Expresion Textil, S.A.

―

Compare ES:PHM Stocks >

Best Analysts Covering PHM

1 Year

Ami FadiaNeedham

1 Year Success Rate

1/5 ratings generated profit

1 Year Average Return

+9.70%

reiterated a buy rating 23 hours ago

Copying Ami Fadia's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +9.70% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Pharma Mar SA (PHM) Price & Analysis

PHM Stock Chart & Stats

Pharma Mar SA News

Financials

Options Prices

Ownership Overview

PHM FAQ

Pharma Mar SA Stock Smart Score

Analyst Consensus

Insider Transactions

News Sentiment

Technicals

Fundamentals

Company Description

Pharma Mar SA

PHM Earnings Call

PHM Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering PHM

Become an Expert with TipRanks Premium